It is a potent and selective sodium glucose co-transporter 2 (SGLT2) ihibibitor used for the treatment of Type 2.It is a SGLT2 inhibitors which reduces glucose reabsorption from PCT increasing the urinary glucose excrection. Beyond the glycemic benefits, GLIFAZ has shown its non glycemic benefits as reduction in blood pressure, body weight, protein excretion and also has proven cardioprotective and renoprotective effect.
